Want to see STXS full AI Analyst Report?
Top Page
Stereotaxis
(STXS)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▲(12.78% Upside)
Action:Reiterated
Date:07/09/26
The score is held down primarily by weak financial performance—large, persistent losses and substantial free-cash-flow burn with modestly declining TTM revenue. Technicals are mixed with the stock still below key longer-term moving averages, limiting momentum support. Offsetting factors include constructive FY2026 growth guidance and strong product/regulatory catalysts highlighted on the earnings call, but execution and cash runway risks keep the overall rating below average.
Positive Factors
Regulatory approvals expand product ecosystem
Multiple FDA approvals (MAGIC PMA, Synchrony clearance, Genesys X) create a regulatory moat and broaden the company's addressable market. These approvals underpin a product ecosystem that supports sustained capital sales, disposables adoption, and long-term clinical credibility across geographies.
Negative Factors
Significant cash burn and negative FCF
Sustained negative operating and free cash flow creates ongoing financing needs and increases dilution or refinancing risk. Continued cash burn constrains the company’s ability to fund manufacturing scale, commercial rollouts, and integration work without external capital, pressuring long‑term financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory approvals expand product ecosystem
Multiple FDA approvals (MAGIC PMA, Synchrony clearance, Genesys X) create a regulatory moat and broaden the company's addressable market. These approvals underpin a product ecosystem that supports sustained capital sales, disposables adoption, and long-term clinical credibility across geographies.
Read all positive factors
Stereotaxis (STXS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$138.28M
Dividend YieldN/A
Average Volume (3M)1.04M
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth-5.47%
EPS Growth13.55%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-0.25
Shares Outstanding100,202,180
10 Day Avg. Volume1,918,848
30 Day Avg. Volume1,043,755
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside125.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$39.40M
Stereotaxis Business Overview & Revenue Model
Company Description
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN...
How the Company Makes Money
Stereotaxis generates revenue primarily by selling and supporting its robotic magnetic navigation systems installed in hospitals and electrophysiology labs. A key recurring component of its model comes from procedure-driven sales of related consum...
Stereotaxis Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call contained multiple material positive operational and commercial milestones (FDA clearances, product launches, strong sequential and year‑over‑year growth in robotically navigated catheter revenue, Synchrony early sales, GenesisX installs and OEM compatibility progress, strategic Robocath acquisition) that point to an improving growth trajectory and a clear path to higher recurring revenue and margin expansion. Offsetting these positives are near‑term execution challenges: supply constraints for MAGiC catheters limiting sales, a YoY decline in system revenue driven by a missed system delivery, depressed system margins due to low volumes, ongoing operating losses and negative free cash flow, and transition‑related procedure pressure. Management provided concrete guidance and reiterated a plan to reach cash‑flow profitability in H1 2027, relying on manufacturing ramp and modest capital sales. Overall, the call indicates constructive commercial inflection and credible progress toward profitability, but with meaningful near‑term operational and financial risks that must be managed.Positive Updates
Recurring revenue momentum driven by robotically navigated catheters
Recurring revenue was $6.2M in Q2 2026 (CEO: recurring revenue surpassed $6M). Robotically navigated catheter revenue exceeded $1M in the quarter and the new catheter portfolio grew rapidly (company reported +270% sequentially and +450% year‑over‑year for robotically navigated catheters; CEO described nearly 300% sequential growth). Management expects ~+$1M incremental catheter revenue in each of the next couple quarters as manufacturing ramps.
Negative Updates
Year‑over‑year decline in system revenue and overall revenue headwind
System revenue declined to $1.5M in Q2 2026 from $3.0M in prior‑year Q2 (‑50% YoY). Overall revenue for the quarter declined YoY due to the lack of a robotic system delivery in the quarter.
Read all updates
Q2-2026 Updates
Positive
Negative
Recurring revenue momentum driven by robotically navigated catheters
Recurring revenue was $6.2M in Q2 2026 (CEO: recurring revenue surpassed $6M). Robotically navigated catheter revenue exceeded $1M in the quarter and the new catheter portfolio grew rapidly (company reported +270% sequentially and +450% year‑over‑year for robotically navigated catheters; CEO described nearly 300% sequential growth). Management expects ~+$1M incremental catheter revenue in each of the next couple quarters as manufacturing ramps.
Read all positive updates
Company Guidance
Management guided that recurring revenue—which was $6.2M of $7.7M total revenue in Q2 (robotic catheter revenue >$1M, up roughly 270–300% sequentially and ~450% YoY)—should rise to approximately $7M in Q3 and $8M in Q4, driven by an expected ~$1M incremental catheter revenue step‑up in each of the next couple quarters as manufacturing ramps (though sales remain supply‑constrained with a backlog). They expect system revenue to rebound from Q2’s $1.5M to about $3M in each of Q3 and Q4 (including recognition of one GenesisX sale in Q3) and see Synchrony supporting >$1M of system revenue per quarter near‑term (ASP ~ $200k). Q2 metrics included overall gross margin 58% (recurring 66%, systems 29%), operating loss $4.6M and net loss $4.5M (adjusted operating loss $2.1M, adjusted net loss $2.0M), operating expenses $9.1M (adjusted $6.6M), negative free cash flow $3.7M, and cash of $10.5M with no debt; management is modeling cash‑flow profitability in H1 2027 and expects recurring gross margins to expand toward the mid‑70s% in 2027–28.Stereotaxis Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.07M | 32.38M | 26.92M | 26.77M | 28.15M | 35.02M |
| Gross Profit | 16.71M | 17.07M | 14.59M | 14.86M | 18.47M | 23.23M |
| EBITDA | -21.13M | -20.09M | -23.08M | -20.12M | -17.86M | -10.60M |
| Net Income | -22.32M | -21.64M | -24.05M | -20.71M | -18.29M | -10.72M |
Balance Sheet | ||||||
| Total Assets | 55.58M | 52.25M | 46.72M | 41.91M | 53.41M | 60.98M |
| Cash, Cash Equivalents and Short-Term Investments | 10.49M | 13.42M | 12.22M | 19.82M | 28.43M | 38.74M |
| Total Debt | 5.17M | 5.44M | 6.01M | 5.49M | 5.86M | 6.11M |
| Total Liabilities | 38.10M | 33.53M | 35.29M | 19.99M | 21.48M | 21.56M |
| Stockholders Equity | 17.48M | 18.72M | 11.43M | 21.92M | 31.93M | 39.42M |
Cash Flow | ||||||
| Free Cash Flow | -15.50M | -13.78M | -8.53M | -9.51M | -10.79M | -4.34M |
| Operating Cash Flow | -15.29M | -13.69M | -8.50M | -9.14M | -8.41M | -2.95M |
| Investing Cash Flow | -1.29M | -93.00K | 74.00K | 19.77M | -22.09M | -1.40M |
| Financing Cash Flow | 20.11M | 14.76M | 297.00K | 81.00K | 220.00K | 547.00K |
Stereotaxis Technical Analysis
Negative
1.33
Price Trends
1.61
Negative
1.76
Negative
2.05
Negative
Market Momentum
-0.06
Negative
42.18
Neutral
48.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Negative. The current price of 1.33 is below the 20-day moving average (MA) of 1.38, below the 50-day MA of 1.61, and below the 200-day MA of 2.05, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 42.18 is Neutral, neither overbought nor oversold. The STOCH value of 48.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STXS.
Stereotaxis Risk Analysis
Stereotaxis disclosed 57 risk factors in its most recent earnings report. Stereotaxis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stereotaxis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $5.42B | 37.04 | 9.07% | ― | 10.51% | 20.67% | |
75 Outperform | $1.88B | 28.41 | 16.42% | 0.94% | 11.85% | 38.09% | |
69 Neutral | $2.25B | 208.77 | 2.14% | ― | 13.94% | ― | |
53 Neutral | $1.31B | 327.25 | 1.08% | ― | 51.30% | ― | |
52 Neutral | $43.93M | -10.38 | -149.08% | ― | 3.72% | 43.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $138.28M | -5.58 | -145.82% | ― | -5.47% | 13.55% |
* Healthcare Sector Average
STXS
Stereotaxis
1.38
-1.40
-50.36%
ATRC
Atricure
44.30
8.68
24.37%
LMAT
Lemaitre Vascular
82.38
-11.79
-12.52%
MMSI
Merit Medical Systems
90.76
4.60
5.34%
STAA
Staar Surgical
26.18
-1.81
-6.47%
MLSS
Milestone Scientific
0.50
-0.14
-21.55%
Stereotaxis Corporate Events
Business Operations and StrategyM&A Transactions
Stereotaxis Advances Vascular Robotics with Robocath Acquisition
Positive
Jul 9, 2026
On July 7, 2026, Stereotaxis completed its previously announced approximately $20 million acquisition of French vascular robotics company Robocath, issuing common shares and pre-funded warrants as consideration and as partial payment to Robocath&#...
Executive/Board ChangesShareholder Meetings
Stereotaxis Shareholders Endorse Board, Auditor and Compensation
Positive
May 15, 2026
On May 14, 2026, Stereotaxis held its Annual Meeting of Shareholders with approximately 65.34% of the 121,182,983 total voting power represented, satisfying quorum requirements. Shareholders voted on the election of three Class I directors to serv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.